Advisors Capital Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 40.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 186,556 shares of the company’s stock after acquiring an additional 53,458 shares during the quarter. Johnson & Johnson makes up approximately 1.3% of Advisors Capital Management LLC’s investment portfolio, making the stock its 16th largest position. Advisors Capital Management LLC’s holdings in Johnson & Johnson were worth $27,213,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. WoodTrust Financial Corp raised its stake in shares of Johnson & Johnson by 4.2% during the 3rd quarter. WoodTrust Financial Corp now owns 46,335 shares of the company’s stock worth $5,995,000 after buying an additional 1,848 shares during the period. Park Avenue Securities LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $2,939,000. Managed Asset Portfolios LLC raised its stake in shares of Johnson & Johnson by 4.3% during the 3rd quarter. Managed Asset Portfolios LLC now owns 181,153 shares of the company’s stock worth $23,438,000 after buying an additional 7,535 shares during the period. Lucia Wealth Services LLC raised its stake in shares of Johnson & Johnson by 2.1% during the 3rd quarter. Lucia Wealth Services LLC now owns 131,950 shares of the company’s stock worth $17,072,000 after buying an additional 2,744 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Johnson & Johnson by 10.0% during the 3rd quarter. Parallel Advisors LLC now owns 31,912 shares of the company’s stock worth $4,129,000 after buying an additional 2,911 shares during the period. 67.28% of the stock is owned by institutional investors.
NYSE JNJ traded down $0.17 during mid-day trading on Friday, hitting $145.22. The stock had a trading volume of 2,569,844 shares, compared to its average volume of 5,766,384. The firm’s 50 day moving average is $142.08 and its 200 day moving average is $134.67. Johnson & Johnson has a twelve month low of $125.00 and a twelve month high of $147.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. The stock has a market capitalization of $381.52 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 2.33 and a beta of 0.71.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The firm had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. During the same period in the prior year, the company earned $2.05 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 8.66 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.62%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Several brokerages have recently weighed in on JNJ. Cantor Fitzgerald began coverage on Johnson & Johnson in a research note on Wednesday, November 27th. They set an “overweight” rating and a $160.00 target price for the company. Raymond James reduced their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Barclays raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.00 to $173.00 in a research note on Thursday, December 19th. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Friday, October 11th. Finally, Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price for the company in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $159.33.
In related news, Director Hubert Joly bought 5,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was bought at an average cost of $141.28 per share, for a total transaction of $706,400.00. Following the acquisition, the director now directly owns 5,000 shares in the company, valued at $706,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 2,017 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total value of $284,538.19. Following the completion of the sale, the executive vice president now owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.